Journal of Clinical Oncology

Journal of Clinical Oncology Journal

Publication venue for

A phase III single-arm study to evaluate the efficacy and safety of paclitaxel-hyaluronic acid conjugate administered intravesically to patients with BCG-unresponsive carcinoma in situ of the bladder with or without Ta-T1 papillary disease (Orion-BC study).. 43:TPS885-TPS885. 2025
First-in-human phase 1/2 study (MYCHELANGELO I) of first-in-class epigenomic controller OTX-2002 targeting MYC oncogene in patients with hepatocellular carcinoma (HCC) and other solid tumors. 43:606-606. 2025
Real-world Child-Pugh scores and outcomes of patients with hepatocellular carcinoma at a high-volume center.. 43:569-569. 2025
Safety, efficacy, and outcomes of 90-yttrium radioembolization in combination with immune checkpoint inhibitors as a definitive first-line treatment approach in non-surgical hepatocellular carcinoma.. 43:617-617. 2025
A multicenter analysis evaluating educational resources utilized by hematology/oncology fellows (HOF). 42. 2024
A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naive, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.. 42. 2024
ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC). 42. 2024
Changes in non-small cell lung cancer (NSCLC) next-generation sequencing (NGS) rates after electronic health record (EHR) integration using large-scale, multi-institutional, real-world data.. 42. 2024
Chemotherapy Care Companion: Enhancing cancer care through digital remote monitoring.. 42. 2024
Cost-effectiveness of a circulating tumor fraction molecular biomarker for treatment response monitoring. 42. 2024
Intervention to improve care delivery and patient self-management for people with primary liver cancer who have socioeconomic disadvantages. 42. 2024
Mutations and mortality in very young patients with breast cancer. 42. 2024
Phase II trial of weekly or bi-weekly tocilizumab with ipilimumab and nivolumab in advanced melanoma: Clinical outcomes and biomarker analysis. 42. 2024
Racial differences in degrees of side effects to taxane based chemotherapy in patients with breast cancer.. 42. 2024
Care delivery and patient self-management for people with primary liver cancer receiving 4R care sequence plans. 42:465-465. 2024
Area deprivation index and breast cancer subtypes in young patients. 41. 2023
Association of intensive chemotherapy with the rate of pathogenic driver mutation clearance in acute myeloid leukemia. 41. 2023
De novo metastatic Her2+breast cancer in a diverse population of women under age 40. 41. 2023
Differences in perceptions and use of remote patient monitoring technology in rural cancer programs. 41. 2023
Early real-world (RW) experience with a multi-cancer early detection (MCED) test.. 41. 2023
Evaluating the diagnostic performance of F-18-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial. 41. 2023
Gaps in care planning and delivery for patients with liver cancer: Baseline assessment for implementation of 4R Oncology model. 41. 2023
Obesity and breast cancer in women under age 40.. 41. 2023
Obesity and triple negative breast cancer diagnosis among premenopausal women.. 41. 2023
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non-Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy. 41:2673-2681. 2023
A phase-Ib study of TRK-950 combined with anticancer treatment regimens in patients with gastric and gastro-esophageal junction (GEJ) cancer.. 41:361-361. 2023
Factors influencing the initiation of adjuvant endocrine therapy in patients with Estrogen receptor-positive ductal carcinoma in situ: A single institution experience.. 40:E18569-E18569. 2022
Implications of 18F-FDG PET/CT findings before autologous stem cell transplant in patients with multiple myeloma.. 40. 2022
Molecular profiling of African American patients with pancreatic cancer.. 40:E16242-E16242. 2022
Pathologic and clinical outcomes after neoadjuvant modified FOLFIRINOX and gemcitabine and NAB-paclitaxel for pancreatic cancer.. 40:E16236-E16236. 2022
Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma.. 40. 2022
A phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 injection alone and in combination with cetuximab in adults with advanced solid tumors and head and neck cancer.. 39. 2021
Survey results of patients with neuroendocrine cancer to find an overall high satisfaction with telemedicine and identify weaknesses of telemedicine unique to patients with rare cancers.. 39. 2021
Validation of a clinical score (CS) for patients (pts) with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177 dotatate.. 39. 2021

International Standard Serial Number (ISSN)

0732-183X